Wide Ranks

BCYC

Bicycle Therapeutics plc

20.35

Top Statistics
Market Cap 1 B Forward PE -5.63 Revenue Growth -50.00 %
Current Ratio 17.13 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -2.77 Enterprise / Revenue 14.24 Price To Sales Trailing12 Months 38.08
Profitability
Profit Margins 0.00 % Operating Margins -2385.87 %
Balance Sheet
Total Cash 890 M Total Cash Per Share 12.90 Total Debt 11 M
Total Debt To Equity 1.33 Current Ratio 17.13 Book Value Per Share 12.04
All Measures
Short Ratio 810.00 % Message Board Id finmb_72510621 Shares Short Prior Month 2 M
Return On Equity -0.2667 City Cambridge Uuid ce2103f4-bc89-3b95-8a05-b5941ff8789d
Previous Close 20.40 First Trade Date Epoch Utc 1 B Book Value 12.04
Beta 0.8920 Total Debt 11 M Volume 193004
Price To Book 1.69 Fifty Two Week Low 14.01 Total Cash Per Share 12.90
Total Revenue 36 M Shares Short Previous Month Date 1 B Target Median Price 35.00
Max Age 86400 Recommendation Mean 1.85 Sand P52 Week Change 0.3133
Operating Margins -2385.87 % Target Mean Price 37.82 Net Income To Common -166276000
Short Percent Of Float 0.0799 Implied Shares Outstanding 69 M Trailing Peg Ratio None
Last Fiscal Year End 1 B Average Daily Volume10 Day 542190 Average Volume10days 542190
Total Cash 890 M Next Fiscal Year End 1 B Revenue Per Share 0.7160
Held Percent Insiders 0.0130 Trailing PE 0.0000 Date Short Interest 1 B
Most Recent Quarter 1 B Regular Market Previous Close 20.40 Target Low Price 25.00
Gmt Off Set Milliseconds -18000000 Fifty Day Average 23.70 Open 20.50
Free Cashflow -141178752 Dividend Yield 0.00 % Return On Assets -0.1502
Time Zone Short Name EST Trailing Eps -3.28 Day Low 20.16
Address1 Portway Building Shares Outstanding 47 M Price Hint 2
Target High Price 55.00 Website https://www.bicycletherapeutics.com 52 Week Change 0.4132
Average Volume 461648 Forward Eps -3.55 Recommendation Key buy
Compensation As Of Epoch Date 1 B Quick Ratio 1682.20 % Is_sp_500 False
Regular Market Day High 20.53 Profit Margins 0.00 % Debt To Equity 1.33
Fifty Two Week High 28.67 Day High 20.53 Shares Short 3 M
Regular Market Open 20.50 Industry Key biotechnology Earnings Growth 0.00 %
Enterprise To Revenue 14.24 Revenue Growth -50.00 % Shares Percent Shares Out 0.0510
Operating Cashflow -202616000 Currency USD Time Zone Full Name America/New_York
Market Cap 1 B Is_nasdaq_100 False Zip CB21 6GS
Quote Type EQUITY Industry Biotechnology Long Name Bicycle Therapeutics plc
Regular Market Day Low 20.16 Held Percent Institutions 0.9237 Current Price 20.35
Address2 Blocks A & B Granta Park Great Abington Enterprise To Ebitda -2.77 Financial Currency USD
Current Ratio 17.13 Industry Disp Biotechnology Number Of Analyst Opinions 11
Country United Kingdom Two Hundred Day Average 23.27 Enterprise Value 525 M
Price To Sales Trailing12 Months 38.08 Forward PE -5.63 Regular Market Volume 193004
Ebitda -189320000 Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom.

Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.

The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors.

In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease.

Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas.

It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV.

Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.